Ofir Dovrat, T., Sokol, E., Frampton, G., Shachar, E., Pelles, S., Geva, R., & Wolf, I. (2018). Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. Cancer Biol Ther.

Ofir Dovrat, Tali, Ethan Sokol, Garrett Frampton, Eliya Shachar, Sharon Pelles, Ravit Geva, and Ido Wolf. "Unusually Long-term Responses to Vemurafenib in BRAF V600E Mutated Colon and Thyroid Cancers Followed By the Development of Rare RAS Activating Mutations." Cancer Biol Ther 2018.

Ofir Dovrat, Tali, et al. "Unusually Long-term Responses to Vemurafenib in BRAF V600E Mutated Colon and Thyroid Cancers Followed By the Development of Rare RAS Activating Mutations." Cancer Biol Ther 2018.